

09-19-01

Receipt

#13



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Vladimir Nikolaevich PAK et al.

U.S. Serial Number:

09/885,645

U.S. Filing Date:

June 20, 2001

Examiner:

Not yet known

Group Number:

Not yet known

Title of Invention:

METHOD FOR TREATMENT OF  
MALIGNANT NEOPLASMS AND A  
COMPLEX PREPARATION HAVING  
ANTIMALIGNANT ACTIVITY

Attorney Docket Number:

53196-00002

Box MISSING PARTS  
Assistant Commissioner for Patents  
Washington, D.C. 20231

<p>CERTIFICATE OF MAILING BY EXPRESS MAIL</p> <p>"EXPRESS MAIL" Label No.: ... EL749039394US Date of Deposit:..... September 17, 2001</p> <p>I hereby certify that this paper, including the documents referred to therein, or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to:</p> <p>Box Missing Parts Assistant Commissioner for Patents Washington, D.C. 20231</p> <p>Type or Print Name: Carla Ekins</p> <p>Signature: <i>Carla Ekins</i></p>
---

Dear Madam or Sir:

**REQUEST TO CORRECT OFFICIAL FILING RECEIPT**

Applicants respectfully request a correction of errors contained in the Official Filing Receipt as pertaining to the above referenced patent application, as mailed on August 22, 2001.

**PATENT APPLICATION**  
**09/885,645**

**DOCKET NUMBER**  
**53196-00002**

**Errors to be corrected:**

1. Total claims listed on the filing receipt is listed incorrectly as one instead of four claims.
2. Independent claims listed on the filing receipt is listed incorrectly as one instead of 2 independent claims.
3. Applicant Anatoli Pavlovich Ogirenko's last name is listed incorrectly as Ognenko instead of Ogirenko.

**Requested Corrections**

1. Please correct the total claims to read "4".
2. Please correct the independent claims to read "2".
3. Please correct the last name of applicant Anatoli Pavlovich Ognenko to read "Ogirenko".

Attached is a copy of the Official Filing Receipt as mailed on August 22, 2001 with red-lined corrections. Applicants do not believe that any fee is due, however, if any fee is due then debit Deposit Account No. 10-0447 of JENKENS & GILCHRIST, P.C.

**PATENT APPLICATION**  
**09/885,654**

**DOCKET NUMBER**  
**53196-00002**

Thank you in advance for your assistance. We will await receipt of the corrected version of the Official Filing Receipt. Please address all future communications concerning this matter to:

Stanley R. Moore, Esq.  
JENKENS & GILCHRIST, P.C.  
1445 Ross Avenue, Suite 3200  
Dallas, Texas 75202-2799.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Stanley R. Moore". The signature is stylized with a large, sweeping initial "S" and a cursive "Moore".

Stanley R. Moore  
Registration No. 26,958

JENKENS & GILCHRIST, P.C.  
1445 Ross Avenue, Suite 3200  
Dallas, Texas 75202-2799  
Telephone: 214-855-4500  
Facsimile: 214-855-4300



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
--------------------	-------------	--------------	---------------	-----------------	----------	------------	------------

09/885,645


06/20/2001

355

53196-  
00002

4 2

23932  
JENKENS & GILCHRIST, PC  
1445 ROSS AVENUE  
SUITE 3200  
DALLAS, TX 75202



PATENT & TRADEMARK OFFICE  
PROPERTY

AUG 24 2001

JENKENS &amp; GILCHRIST

CONFIRMATION NO. 4188

## FILING RECEIPT



\*OC000000006459884\*

Date Mailed: 08/22/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Vladimir Nikolaevich Pak, Novosibirsk, RUSSIAN FEDERATION;  
Natalia Anatolievna Pak, Novosibirsk, RUSSIAN FEDERATION;  
Sergei Stepanovich, Novosibirsk, RUSSIAN FEDERATION;  
Sergei Danilovich Nikonov, Novosibirsk, RUSSIAN FEDERATION;  
Anatoli Pavlovich Ognenko, Novosibirsk, RUSSIAN FEDERATION;

Ognenko

\* DOCKETED  
Int: KA DT: 82801  
Action Complete Date: 824  
Filing Receipt w/nmp

Domestic Priority data as claimed by applicant

## Foreign Applications

RUSSIAN FEDERATION 2000116417 06/22/2000

If Required, Foreign Filing License Granted 08/22/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

## Title

Method for treatment of malignant neoplasms and a complex preparation having antimalignant

activity


**Preliminary Class**

---

**Data entry by :** VORACHACK, CHUNTASORN

**Team :** OIPE

**Date:** 08/22/2001



**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**PLEASE NOTE the following information about the Filing Receipt:**

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents  
 Office of Initial Patent Examination  
 Customer Service Center  
 Washington, DC 20231